Tel Aviv University announces $20m commercialisation fund with Tata Industries.

Kaiser Permanente Ventures and GE Asset Management are in the F round.

The money will be primarily used to support the planned commercial launch of the company's RhythmView WorkStation and FirMap Catheter in Europe and the US this year.

Gen9's previous investors include food maker Kraft Group, venture capital firms Draper Fisher Jurvetson and PBM Capital Group and angel investors, including Scott Schoen, former co-president of buyout firm Thomas H lee, and Weili Dai, co-founder of Marvell Technology Group.

Enterprise performance applications provider Anaplan has expanded its series C round to $33m with participation from software provider Salesforce.

Gene control life sciences company Syros Pharmaceuticals has raised its first ever round of funding with a $30m series A round from Flagship Ventures, Arch Venture Partners and WuXi PharmTech Corporate Venture Fund.

Cloud integration service MuleSoft brings its total funding to over $80m with a $37m series E round led by New Enterprise Associates.